Torpid Outlook Knocks NitroMed
NitroMed (NTMD) reported first-quarter results that didn't meet Wall Street's expectations, and it said full-year sales would be well below the consensus estimate, sinking the drugmaker's shares.
By late morning, the stock was down $2.21, or 25.7%, to $6.40. The stock fell as low as $6.33, a 52-week low. Trading volume was triple the average daily volume of 701,000 shares for the past three months.
NitroMed, based in Lexington, Mass., makes BiDil, a congestive heart failure drug for African-Americans. BiDil is the first medication approved by the Food and Drug Administration for a specific ethnic group. BiDil reached the market in July 2005.
However, BiDil's sales have been beset by an assortment of problems, including the reluctance by many managed-care organizations to provide the drug with low out-of-pocket charges for their clients.In addition, the company's hiring of representatives on a contract basis proved ineffective, and NitroMed is hiring its own sales force. The sales-force transition will be completed by the end of the month. The reimbursement and sales problems spilled over into the first-quarter results, as NitroMed recorded a loss of $25.9 million, or 75 cents a share, on sales of $2.32 million. Analysts polled by Thomson First Call had expected a loss of 68 cents a share and sales of $5 million. NitroMed didn't have any product sales in the year-ago quarter. The company also predicted that full-year sales would be $20 million, less than half of the $44.4 million consensus forecast. Recent prescription data suggest that BiDil "is gaining traction," Argeris Karabelas, NitroMed's chairman and interim CEO, told analysts during a telephone conference call. First-quarter operating expenses were higher year over year partly because of the launch of BiDil. However, NitroMed also had $2 million in restructuring charges after discontinuing many of its research projects and firing 30% of its staff. The latest first quarter also included $1.7 million in stock-based compensation expenses.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV